Peripheral blood stem cells (PBSCs) are being used as an alternative to autologous marrow rescue for hematopoietic reconstitution after high-dose chemotherapy in patients with neuroblastoma and other solid malignancies. Use of PBSCs is preferred by some because of the belief that there is less risk of tumor contamination. Because tumor stem cell contamination is thought to be one contributing cause of relapse after myeloablative therapy and autologous reconttitution, we examined the potential risk of reinfusing circulating neuroblastoma cells by in vitro evaluation of their clonogenicity. lmmunocytologic and tumor cell clonogenic analyses were performed on 74 blood samples obtained from 56 children with advanced-stage neuroblastoma. Concurrently drawn bone marrow specimens were evaluated in 30 instances, Circulating neoplastic cells were detected in 19 of 74 (26%) for all specimens and by immunologic techniques ERIPHERAL BLOOD stem cells (PBSCs) are being used with increasing frequency to enhance hematopoietic reconstitution after myeloablative therapy for a number of disseminated malignancies.'" To rescue the patient from lethal chemoradiotherapy, PBSCs are infused either alone or in conjunction with m a r r o~.~"~ PBSCs are also used to limit the neutropenic phase of patients undergoing conventional chemotherapy. Conditions currently being treated in this way include lymphoma, leukemia, myeloma, neuroblastoma, breast carcinoma, and ovarian carcinoma, as well as a number of other solid malignan~ies.l-~~' PBSC reinfusion is gaining popularity because (1) the cells are easy to collect; (2) rapid hematopoietic recovery is achievable; and (3) PBSC collections may circumvent tumor contamination likely to be present in the bone marrow and are supposedly free of tumor contamination.
It has recently been shown that circulating malignant cells can contaminate PBSC harvests from patients with neuroblastoma, breast carcinoma, Hodgkin's lymphoma, and nonHodgkin's lyrnph~ma.""~ No studies have been reported regarding their clonogenicity; thus, the clinical significance of reinfusing neoplastic cells into the patient is unknown.
Because tumor stem cells are thought to be responsible for the relapse of disease,15 we examined the potential risk of reinfusing circulating neuroblastoma cells by evaluating their clonogenic growth in vitro. We analyzed mononuclear cells isolated from blood specimens obtained at diagnosis and during therapy from 46 children with disseminated neuroblastoma in a soft agar tumor colony assay. Blood specimens were also evaluated with a highly sensitive and specific immunocytologic assay to determine the concentration of circulating malignant cells. stage I1 disease) were analyzed. There were 19 females and 37 males analyzed with an age range of 5 to 161 months (median, 33 months). Nine blood specimens were obtained at the time of diagnosis, 27 samples were analyzed 1 to 7 months after diagnosis, and 38 samples were drawn and evaluated greater than 7 months after diagnosis. Concurrently drawn bone marrows were available for immunocytologic analysis in 30 cases (6 at diagnosis, 13 at I to 7 months, and 1 1 after 7 months).
P

MATERIALS AND METHODS
Patient
Monoclonal antibodies (MoAbs). Neuroblastoma cells are known to express a number of surface antigensT6"' not expressed by normal hematopoietic cells. A panel of four antineuroblastoma MoAbs was used for tumor cell detection and colony verification by immunostaining target antigens. The specific antibodies and corresponding antigens are shown in Table  Cell lines. Human neuroblastoma cell lines LA-N-1 and LA-N-5 were cultured at 37°C in Liebowitz L-l5 medium (L-15) supplemented with 15% heat-inactivated fetal bovine serum (FBS), glutamine (100 mmollL), and penicillin (1,000,000 UL). Cells were removed for immunostaining when the flasks were confluent.
Preparation of peripheral blood and bone marrow. Methods for cell preparation and immunostaining have been previously reBriefly, blood was obtained from a central venous catheter or from the antecubital fossa and bone marrow was drawn from the posterior iliac crests. Approximately 3 to 5 mL of blood was collected in heparinized tubes before processing. Samples from the refemng hospitals arrived within 24 hours and all specimens were processed within 48 hours of collection.
Upon arrival in the laboratory, the blood was diluted to I O mL with L-l5 supplemented with 10% FBS (GIBCO, Grand Island,
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MOSS ET AL NY). Diluted samples were layered over Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) and then subjected to density gradient centrifugation. The mononuclear cell fraction was tested for viability (Trypan blue exclusion), counted by a hemacytometer, and resuspended in L-lS/FBS. Cell lines were removed with trypsin EDTA and washed with L-lS/FBS. The four MoAb mixture was then added to 1 mL of the cell suspension (blood or cell lines) and incubated at room temperature. After incubation, the cells were washed, cytocentrifuged onto coverslips (75,000 nucleated cells per coverslip), and stored at 4°C for future immunoperoxidase staining.
Immunostaining. Cell lines and patient specimens were removed from storage and tested for immunoreactivity. Immunostaining was accomplished using the avidin biotin-peroxidase technique (ABC method).22 Coverslips were incubated in a paraformaldehyde/methano1 fixative, followed by normal goat serum, biotinylated goat antimouse Ig (Vector Laboratories, Burlingame, CA), phenylhydrazine (Sigma, St Louis, MO) to block endogenous peroxidase, and then avidin-biotin-peroxidase complexes (Vector Laboratories). Visualization of bound peroxidase was made possible by incubation with diaminobenzidene/H202 (diluted in citrate buffer, 0.3% H,O,) followed by Ehrlich's hematoxylin counterstain. Coverslips were dehydrated with ethyl alcohol and Xylene and attached to slides with Cytoseal.
Analysis for circulating neuroblastoma cells. Neuroblastoma cells were identified both immunologically (positive immunostaining on at least 50% of the surface membrane) and morphologically (large cells alone or in clusters with high nuclear to cytoplasmic ratio, with no clumping of chromatin, and with prominent nucleoli). To minimize the possibility of false-positive analysis, detection of at least two tumor cells was required before a blood specimen was recorded as positive. Quantitation of neuroblastoma cells was performed for each specimen by the following criteria. For samples containing tumor cell concentrations greater than O S % , 4 fields of 200 cells each were assessed on at least 2 slides; for specimens with fewer than 0.5% tumor cells, at least 4 slides, each containing 50,000 cells, were evaluated.
Neuroblastoma tumor colony assay. Ten million mononuclear cells from blood samples were added to 3 mL of double-strength Iscove's modified Dulbecco's medium (IMDM; Sigma) and combined with 2 mL of heat-inactivated FJ3S (GIBCO). The media cell mixture was added to 5 mL of 0.6% sea-plaque agar (Sigma) and l x IO6 cells (1 mL) were placed in 35-mm petri dishes containing growth factors (20 U recombinant human granulocyte-macrophage colony-stimulating factor [GM-CSF; Amgen, Thousand Oaks, CAI; 5 ng 7-S nerve growth factor; and 5 ng recombinant human insulin growth factor-] [Collaborative Research, Boston, MA]). Cells incubated without growth factors served as negative controls. All cultures were plated in triplicate. Plates were incubated for 10 days in a 100% humidified chamber at 37°C with 5% CO2. Tumor colonies were defined as aggregates of 50 or more cells. They were identified and enumerated by phase microscopy. 
t Number of colonies per plate (lo6 mononuclear cells plated).
Verijication of tumor colony count. To assist with identification of colonies, the following immunofluorescent protocol was developed. The petri dish was removed from the incubator and allowed to cool for 1 hour at room temperature. The agar was removed from the plate by immersion in a bath of distilled water. The agar was floated onto a glass slide and stored overnight at 4°C. The next day, slides were fixed with parafomddehyde/methanol, blocked with 10% normal goat serum, and then incubated overnight with the four antineuroblastoma MoAb mixture. The agar slides were then incubated with fluorescein-labeled goat-antimouse IgG (Coulter, Hialeah, FL) and examined under a fluorescent microscope to confirm tumor-specific immunostaining of suspected tumor-cell colonies.
Plating efficiency of circulating neuroblastoma cells. For specimens that had detectable neuroblastoma cells and yielded malignant colonies, it was possible to determine the tumor cell plating efficiency by the following formula:
No. of Tumor Colonies No. of Neuroblastoma Cells Plated x 100
In this formula, the number of neuroblastoma cells plated was arrived at by multiplying the immunocytologically determined tumor cell concentration by lo6. For example, if the blood sample contained 5 neuroblastoma cells per 10' mononuclear cells and we plated IOb marrow cells, the total number of neuroblastoma cells plated was 50 ([5 + IO'] X lo6 = 50). and in 4 of 39 taken after 7 months. Tumor cell concentrations ranged from 1 to 160 per 10' mononuclear cells with a median of 5 per los (Table 2 ). An example of circulating neuroblastoma cells identified by immunoperoxidase staining is shown in Fig 1. Clonogenic analvsis of blood specimens. Three of the 74 samples could not be evaluable because of bacterial contamination. Tumor colonies grew from 13 specimens, from 5 samples at diagnosis, from 5 samples at I to 7 months, and from 3 samples after 7 months. The number of colonies ranged from I to 40 per plate, with a median of 3 ( Table  2 ). Of the 19 samples positive by immunocytologic analysis, I O produced neuroblastoma colonies; of the 53 specimens negative by immunocytology, 3 grew neoplastic colonies. Examples of tumor colonies are shown in Fig 2. Tumor cell plating efficiency could be calculated for IO specimens. Plating efficiencies ranged from 0.9% to 50%, with a median of 6% (Table 2 ). There was no significant difference in the efficiency of specimens obtained at diagnosis versus those obtained later (medians of both, 6.0%).
RESULTS
Immunocytologic analysis
Immunocytologic evaluation of bone marrow. Concurrently drawn bone marrow specimens were evaluated for tumor cell contamination in 30 instances. Metastatic neuroblastoma cells were detected in 5 of 6 samples obtained at diagnosis, in 4 of 13 analyzed at I to 7 months, and in 3 of 1 I drawn after 7 months ( Table 3) . The tumor concentration ranged from 2 to 80,000 per IO" mononuclear cells, with a median of 43 per IO'. Of the 1 1 positive blood samples. 9 concurrent marrows contained neuroblastoma cells; of the 19 negative blood specimens, 3 concurrent marrows had metastatic disease ( Table 3) .
DISCUSSION
PBSC reinfusion is one way of using a "supposedly" tumor-free marrow stem cell product for hematopoietic re- Little is known about the clinical significance of occult neoplastic cells in PBSC harvests. In this study, 26% of the specimens (7 of 26) were drawn during induction therapy. The majority of these positive samples had tumor stem cells identified by colony growth. An additional 8% of specimens believed to be negative (3 of 39) grew malignant colonies. Thus, the risk of viable tumor cells in PBSC harvests appears to be much greater than the previously reported incidence of 15%.12 This difference may in part be due to patient selection, where only children with good partial or complete responses to therapy are transplanted.
It is now possible to estimate the number of tumor stem cells that may be reinfused into autologous transplant recipients whose harvests are contaminated. A 20-kg child will have approximately 1 to 3 X 10" mononuclear cells infused for a standard PBSC transplant. Using our median tumor concentration found in the blood specimens of 5 neuroblastoma cells per lo5 mononuclear cells, the harvest will approximately contain between 500,000 and 1,500,000 neoplastic cells. Assuming a plating efficiency of 6.4%, reinfusion of that contaminated harvest will result in 32,000 to 96,000 tumor stem cells (500,000 to 1,500,000 X 0.064) reentering the patient at the time of reinfusion. This underscores concerns regarding the clinical safety of infusing PBSC collections that have not been assayed for potential tumor contamination.
The high plating efficiencies observed in our preliminary study indicate that circulating neuroblastoma cells in patients may be particularly aggressive. The reported plating efticiency of primary and metastatic tumors in agar culture is substantially lower (t0.2%). '3,24 In addition, previous reports on the clonogenicity of 6 neuroblastoma cell lines. obtained from clinically virulent tumors, showed a plating efficiency ranging from 1.0% to 27%, with a median of only 2.4%.2r-27 Thus, circulating neuroblastoma cells may have a greater growth potential than primary and metastatic neoplastic cells and may be similar to that observed in cell lines. However, because the number of samples and colonies per specimen are small, further evaluation is necessary before definitive conclusions can be made. The use of PBSC collections is becoming a major therapeutic modality after conventional and myeloablative therapy. However, our data suggest that enthusiasm for this technique should be tempered with caution in patients with neuroblastoma. Currently, some clinical trials are being performed without adequate testing for tumor cell contamination. Our observations are in accord with previous reports that demonstrate the regularity with which neoplastic cells circulate and contaminate PBSC harvests. Moreover, we have shown these cells to be highly clonogenic and, if reinfused, to carry the potential to re-establish the malignant process.
Based on our observations, we recommend that future prospective clinical trials using PBSC collections address the issue of tumor cell contamination. If tumor contamination is detected, some form of purging procedure (MoAb or chemotherapeutic) of these specimens may be warranted. For personal use only. on October 30, 2017. by guest www.bloodjournal.org From
